Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
42
CMPS Quote, Financials, Valuation and Earnings
Last price:
$6.85
Seasonality move
:
-16.78%
Day range:
$6.81 - $7.12
52-week range:
$2.25 - $8.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
18.01x
Volume:
1.9M
Avg. volume:
3.8M
1-year change:
83.12%
Market cap:
$676.9M
Revenue:
--
EPS (TTM):
-$2.68
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CMPS
Compass Pathways Plc
|
-- | -$0.39 | -- | -46.69% | $21.92 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -- | -- | -- |
|
SLNCF
Silence Therapeutics Plc
|
$1.6M | -$0.15 | 700.8% | -12.5% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CMPS
Compass Pathways Plc
|
$7.05 | $21.92 | $676.9M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$0.94 | $17.94 | $788.5K | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$2.13 | $104.00 | $8.9M | -- | $0.00 | 0% | -- |
|
OXBDF
Oxford Biomedica Plc
|
$8.75 | -- | $1.1B | -- | $0.00 | 0% | 4.74x |
|
SLNCF
Silence Therapeutics Plc
|
$1.75 | -- | $248M | -- | $0.00 | 0% | 123.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CMPS
Compass Pathways Plc
|
48.35% | 1.075 | 6.4% | 0.94x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.660 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.264 | 0.95% | 4.03x |
|
OXBDF
Oxford Biomedica Plc
|
37.49% | 2.394 | -- | 1.99x |
|
SLNCF
Silence Therapeutics Plc
|
0.25% | 4.663 | 0.09% | 5.88x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CMPS
Compass Pathways Plc
|
-$14.9K | -$40.3M | -129.92% | -159.15% | -- | -$34.8M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -90.47% | -120.93% | -- | -- |
|
SLNCF
Silence Therapeutics Plc
|
-$20.5K | -$23.7M | -101.67% | -101.79% | -14881.13% | -$11M |
Compass Pathways Plc vs. Competitors
-
Which has Higher Returns CMPS or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Compass Pathways Plc's net margin of --. Compass Pathways Plc's return on equity of -159.15% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital CMPSCompass Pathways Plc-- -$1.44 $72.8M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About CMPS or BDRX?
Compass Pathways Plc has a consensus price target of $21.92, signalling upside risk potential of 210.88%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 18820.35%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Compass Pathways Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Compass Pathways Plc.
Company Buy Ratings Hold Ratings Sell Ratings CMPSCompass Pathways Plc7 1 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is CMPS or BDRX More Risky?
Compass Pathways Plc has a beta of 1.901, which suggesting that the stock is 90.136% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.022, suggesting its more volatile than the S&P 500 by 2.181%.
-
Which is a Better Dividend Stock CMPS or BDRX?
Compass Pathways Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Pathways Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPS or BDRX?
Compass Pathways Plc quarterly revenues are --, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Compass Pathways Plc's net income of -$136.9M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Compass Pathways Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Pathways Plc is -- versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPSCompass Pathways Plc-- -- -- -$136.9M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns CMPS or NCNA?
NuCana Plc has a net margin of -- compared to Compass Pathways Plc's net margin of --. Compass Pathways Plc's return on equity of -159.15% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital CMPSCompass Pathways Plc-- -$1.44 $72.8M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About CMPS or NCNA?
Compass Pathways Plc has a consensus price target of $21.92, signalling upside risk potential of 210.88%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 976425.82%. Given that NuCana Plc has higher upside potential than Compass Pathways Plc, analysts believe NuCana Plc is more attractive than Compass Pathways Plc.
Company Buy Ratings Hold Ratings Sell Ratings CMPSCompass Pathways Plc7 1 0 NCNANuCana Plc0 1 0 -
Is CMPS or NCNA More Risky?
Compass Pathways Plc has a beta of 1.901, which suggesting that the stock is 90.136% more volatile than S&P 500. In comparison NuCana Plc has a beta of 1.688, suggesting its more volatile than the S&P 500 by 68.831%.
-
Which is a Better Dividend Stock CMPS or NCNA?
Compass Pathways Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Pathways Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPS or NCNA?
Compass Pathways Plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Compass Pathways Plc's net income of -$136.9M is lower than NuCana Plc's net income of -$378.9K. Notably, Compass Pathways Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Pathways Plc is -- versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPSCompass Pathways Plc-- -- -- -$136.9M NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns CMPS or OXBDF?
Oxford Biomedica Plc has a net margin of -- compared to Compass Pathways Plc's net margin of --. Compass Pathways Plc's return on equity of -159.15% beat Oxford Biomedica Plc's return on equity of -120.93%.
Company Gross Margin Earnings Per Share Invested Capital CMPSCompass Pathways Plc-- -$1.44 $72.8M OXBDFOxford Biomedica Plc-- -- $140.3M -
What do Analysts Say About CMPS or OXBDF?
Compass Pathways Plc has a consensus price target of $21.92, signalling upside risk potential of 210.88%. On the other hand Oxford Biomedica Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Compass Pathways Plc has higher upside potential than Oxford Biomedica Plc, analysts believe Compass Pathways Plc is more attractive than Oxford Biomedica Plc.
Company Buy Ratings Hold Ratings Sell Ratings CMPSCompass Pathways Plc7 1 0 OXBDFOxford Biomedica Plc0 0 0 -
Is CMPS or OXBDF More Risky?
Compass Pathways Plc has a beta of 1.901, which suggesting that the stock is 90.136% more volatile than S&P 500. In comparison Oxford Biomedica Plc has a beta of 1.131, suggesting its more volatile than the S&P 500 by 13.064%.
-
Which is a Better Dividend Stock CMPS or OXBDF?
Compass Pathways Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oxford Biomedica Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Pathways Plc pays -- of its earnings as a dividend. Oxford Biomedica Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPS or OXBDF?
Compass Pathways Plc quarterly revenues are --, which are larger than Oxford Biomedica Plc quarterly revenues of --. Compass Pathways Plc's net income of -$136.9M is higher than Oxford Biomedica Plc's net income of --. Notably, Compass Pathways Plc's price-to-earnings ratio is -- while Oxford Biomedica Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Pathways Plc is -- versus 4.74x for Oxford Biomedica Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPSCompass Pathways Plc-- -- -- -$136.9M OXBDFOxford Biomedica Plc4.74x -- -- --
-
Which has Higher Returns CMPS or SLNCF?
Silence Therapeutics Plc has a net margin of -- compared to Compass Pathways Plc's net margin of -13181.13%. Compass Pathways Plc's return on equity of -159.15% beat Silence Therapeutics Plc's return on equity of -101.79%.
Company Gross Margin Earnings Per Share Invested Capital CMPSCompass Pathways Plc-- -$1.44 $72.8M SLNCFSilence Therapeutics Plc-12.89% -$0.15 $74.2M -
What do Analysts Say About CMPS or SLNCF?
Compass Pathways Plc has a consensus price target of $21.92, signalling upside risk potential of 210.88%. On the other hand Silence Therapeutics Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Compass Pathways Plc has higher upside potential than Silence Therapeutics Plc, analysts believe Compass Pathways Plc is more attractive than Silence Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings CMPSCompass Pathways Plc7 1 0 SLNCFSilence Therapeutics Plc1 0 0 -
Is CMPS or SLNCF More Risky?
Compass Pathways Plc has a beta of 1.901, which suggesting that the stock is 90.136% more volatile than S&P 500. In comparison Silence Therapeutics Plc has a beta of 0.764, suggesting its less volatile than the S&P 500 by 23.608%.
-
Which is a Better Dividend Stock CMPS or SLNCF?
Compass Pathways Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Silence Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Pathways Plc pays -- of its earnings as a dividend. Silence Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPS or SLNCF?
Compass Pathways Plc quarterly revenues are --, which are smaller than Silence Therapeutics Plc quarterly revenues of $159K. Compass Pathways Plc's net income of -$136.9M is lower than Silence Therapeutics Plc's net income of -$21M. Notably, Compass Pathways Plc's price-to-earnings ratio is -- while Silence Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Pathways Plc is -- versus 123.28x for Silence Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPSCompass Pathways Plc-- -- -- -$136.9M SLNCFSilence Therapeutics Plc123.28x -- $159K -$21M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 6.21% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is down 6.38% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 7.22% over the past day.
